Tag Archives: Cerulean Pharma

May, 2015

  • 28 May

    Cerulean Pharma’s Ovarian Cancer Drug Granted Orphan Drug Status

    The US Food and Drug Administration (FDA) has granted Orphan Drug designation to Cerulean Pharma Inc.’s investigational ovarian cancer drug. The company announced that the agency granted the designation to its nanoparticle-drug conjugate (NDC), CRLX101, for the treatment of patients with ovarian cancer. The designation provides certain incentives, such as …